TopoTarget and CuraGen Initiate Clinical Trial of PXD101 and Azacytidine

TopoTarget A/S and CuraGen Corp. have announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase, HDAC, inhibitor, in combination with Azacytidine for the treatment of advanced hematologic malignancies. This trial is being sponsored by the National Cancer Institute, NCI, under a clinical Trials Agreement with CuraGen for the development of PXD101.

The Phase I trial is an open-label, dose escalation study. The study aims to establish the maximum tolerated dose, MTD, and safety profile of PXD101 in combination with Azacytidine for patients with advanced hematologic cancers, including relapsed or refractory acute myelogenous leukaemia, acute lymphoblastic leukaemia, chronic myelogenous lukemia, or myelodysplastic syndromes. Up to fifteen patients will be enrolled in the study and receive PXD101 and Azacytidine in continuous four week cycles until disease progression.

For further information, please contact:

Peter Buhl Jensen,

CEO

Tel: +45 39 17 83 41

Email:enquiries@topotarget.com

Or visit: www.topotarget.com